Paul Y. Song - Sep 28, 2023 Form 3 Insider Report for NKGen Biotech, Inc. (GFOR)

Role
Chief Executive Officer, Director
Signature
/s/ Pierre Gagnon, Attorney-in-fact
Stock symbol
GFOR
Transactions as of
Sep 28, 2023
Transactions value $
$0
Form type
3
Date filed
10/10/2023, 04:06 PM
Next filing
Nov 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding GFOR Common Stock 170K Sep 28, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding GFOR Stock Option (right to buy) Sep 28, 2023 Common Stock 393K $6.67 Direct F1, F2
holding GFOR Stock Option (right to buy) Sep 28, 2023 Common Stock 83.7K $6.67 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date of February 3, 2022, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
F2 Dr. Song was elected as a member of the board of directors and appointed as President and Chief Executive Officer of the Issuer effective immediately after the Effective Time (as defined in the Business Combination Agreement, dated April 14, 2023 (the "Business Combination Agreement"), by and among the Issuer, Austria Merger Sub, Inc., and NKGen Biotech, Inc.). In connection with the Closing (as defined in the Business Combination Agreement) and prior to Dr. Song joining the board of directors and being appointed an executive officer of the Issuer, Dr. Song exchanged his options to acquire shares of common stock of NKGen Biotech, Inc. for options to acquire shares of the Issuer.
F3 One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date of December 28, 2022, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

Remarks:

See attached Exhibit 24 - Power of Attorney